Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Dec. 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0739405/Fabry's-Disease-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Fabry's Disease Therapeutics market. The report identifies the key trends shaping and driving the global Fabry's Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Fabry's Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Fabry's Disease Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Fabry's Disease Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Fabry's Disease Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Fabry's Disease Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Fabry's Disease Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Fabry's Disease Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Fabry's Disease Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Fabry's Disease Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Fabry's Disease Therapeutics - Introduction 7

2.1 Overview 7

2.2 Epidemiology 8

2.3 Etiology 8

2.4 Symptoms 9

2.5 Diagnosis 11

2.6 Pathophysiology 12

2.7 Treatment and Management Pattern 13

2.8 GlobalData Pipeline Report Guidance 13

3 Fabry's DiseaseTherapeutics - Market Characterization 14

3.1 Fabry's Disease Therapeutics Market Size (2005-2010) - Global 14

3.2 Fabry's Disease Therapeutics Market Forecast (2010-2018) - Global 16

3.3 Fabry's Disease Therapeutics Market Size (2005-2010) - The US 17

3.4 Fabry's Disease Therapeutics Market Forecast (2010-2018) - The US 18

3.5 Fabry's Disease Therapeutics Market Size (2005-2010) - France 19

3.6 Fabry's Disease Therapeutics Market Forecast (2010-2018) - France 20

3.7 Fabry's Disease Therapeutics Market Size (2005-2010) - Germany 21

3.8 Fabry's Disease Therapeutics Market Forecast (2010-2018) - Germany 22

3.9 Fabry's Disease Therapeutics Market Size (2005-2010) - Italy 23

3.10 Fabry's Disease Therapeutics Market Forecast (2010-2018) - Italy 24

3.11 Fabry's Disease Therapeutics Market Size (2005-2010) - Spain 25

3.12 Fabry's Disease Therapeutics Market Forecast (2010-2018) - Spain 26

3.13 Fabry's Disease Therapeutics Market Size (2005-2010) - The UK 27

3.14 Fabry's Disease Therapeutics Market Forecast (2010-2018) - The UK 28

3.15 Fabry's Disease Therapeutics Market Size (2005-2010) - Japan 29

3.16 Fabry's Disease Therapeutics Market Forecast (2010-2018) - Japan 30

3.17 Drivers and Barriers for the Fabry's Disease Therapeutics Market 31

3.17.1 Drivers for the Fabry's Disease Therapeutics Market 31

3.17.2 Barriers for the Fabry's Disease Therapeutics Market 32

3.18 Opportunity and Unmet Need 32

3.19 Key Takeaway 33

4 Fabry's Disease Therapeutics - Competitive Assessment 34

4.1 Overview 34

4.2 Strategic Competitor Assessment 34

4.3 Product Profile for Major Marketed Products in the Fabry's Disease Therapeutics Market 35

4.3.1 Fabrazyme (agalsidase beta) 35

4.3.2 Replagal (agalsidase alfa) 37

4.4 Key Takeaway 39

5 Fabry's Disease Therapeutics - Pipeline Assessment 40

5.1 Overview 40

5.2 Strategic Pipeline Assessment 40

5.3 Fabry's Disease - Pipeline Analysis by Phase of Development 40

5.3.1 Fabry's Disease - Phase III Pipeline 40

5.3.2 Fabry's Disease - Preclinical Pipeline 40

5.4 Fabry's Disease - Pipeline by Mechanism of Action 41

5.5 Technology Trends Analytical Framework 42

5.6 Most Promising Drug Profiles 43

5.6.1 Amigal (AT1001, migalastat hydrochloride) 43

5.6.2 Amigal (migalastat hydrochloride) + Enzyme Replacement Therapy 43

5.7 Key Takeaway 44

6 Fabry's Disease Therapeutics - Clinical Trials Mapping 45

6.1 Clinical Trials by Region and Country 45

6.2 Clinical Trials by Phase of Clinical Development 46

6.3 Clinical Trials by Trial Status 47

6.4 Clinical Trials by Sponsors 48

6.5 Top Companies Participating in Fabry's Disease Clinical Trials 50

7 Fabry's Disease Therapeutics - Strategic Assessment 51

7.1 Key Events Impacting the Future Market 51

7.2 Future Market Competition Scenario 52

8 Fabry's Disease Therapeutics - Future Players 54

8.1 Introduction 54

8.2 Company Profiles 55

8.2.1 GlaxoSmithKline 55

8.2.2 Amicus 56

8.3 Details of Other Companies in the Pipeline 58

8.4 Key Takeaway 59

9 Fabry's Disease Therapeutics - Licensing and Partnership Deals 60

10 Fabry's Disease Therapeutics - Appendix 61

10.1 Definitions 61

10.2 Acronyms 61

10.3 Research Methodology 62

10.3.1 Coverage 62

10.3.2 Secondary Research 62

10.3.3 Forecasting 63

10.3.4 Primary Research 66

10.3.5 Expert Panel Validation 66

10.4 Contact Us 66

10.5 Disclaimer 66

10.6 Bibliography 67

List of Tables

Table 1: Fabry's Disease Market, Global, Revenue ($m), 2005-2010 15

Table 2: Fabry's Disease Market, Global, Forecast ($m), 2010-2018 16

Table 3: Fabry's Disease Market, The US, Revenue ($m), 2005-2010 17

Table 4: Fabry's Disease Market, The US, Forecast ($m), 2010-2018 18

Table 5: Fabry's Disease Market, France, Revenue ($m), 2005-2010 19

Table 6: Fabry's Disease Market, France, Forecast ($m), 2010-2018 20

Table 7: Fabry's Disease Market, Germany, Revenue ($m), 2005-2010 21

Table 8: Fabry's Disease Market, Germany, Forecast ($m), 2010-2018 22

Table 9: Fabry's Disease Market, Italy, Revenue ($m), 2005-2010 23

Table 10: Fabry's Disease Market, Italy, Forecast ($m), 2010-2018 24

Table 11: Fabry's Disease Market, Spain, Revenue ($m), 2005-2010 25

Table 12: Fabry's Disease Market, Spain, Forecast ($m), 2010-2018 26

Table 13: Fabry's Disease Market, The UK, Revenue ($m), 2005-2010 27

Table 14: Fabry's Disease Market, The UK, Forecast ($m), 2010-2018 28

Table 15: Fabry's Disease Market, Japan, Revenue ($m), 2005-2010 29

Table 16: Fabry's Disease Market, Japan, Forecast ($m), 2010-2018 30

Table 17: Reduction of GL-3 Inclusions to Normal or Near-normal Levels (0 Score) in the Capillary Endothelium of the Kidney, Heart, and Skin 36

Table 18: Summary of Clinical Trials for Replagal 39

Table 19: Fabry's Disease Therapeutics - Phase III Clinical Pipeline, 2011 40

Table 20: Fabry's Disease Therapeutics - Pre-Clinical and Discovery Pipeline, 2011 40

Table 21: Fabry's Disease, Global, Clinical Trials, 2011 45

Table 22: Fabry's Disease, Global, Clinical Trials by Phase, 2011 46

Table 23: Fabry's Disease, Global, Clinical Trials by Status of Development, 2011 47

Table 24: Fabry's Disease, Global, Overall Sponsors, 2011 48

Table 25: Fabry's Disease, Global, Prominent Sponsors, 2011 49

Table 26: Fabry's Disease, Global, Top Companies by Phase, 2011 50

Table 27: GlaxoSmithKline, Pipeline - 2011 56

Table 28: Amicus, Pipeline - 2011 57

Table 29: Description of Other Companies in the Pipeline, 2011 58

Table 30: Fabry's Disease Therapeutics, Global, Deals, 2011 60

List of Figures

Figure 1: Fabry's Disease - Illustration of Fabry's Disease Timeline 7

Figure 2: Fabry's Disease - Inheritance Pattern 8

Figure 3: Fabry's Disease - Signs and Symptoms 9

Figure 4: Fabry's Disease - Signs and Symptoms 10

Figure 5: Fabry's Disease - Misdiagnosis of Fabry's Disease 11

Figure 6: Fabry's Disease - Clinical Effects on Various Organ Systems 12

Figure 7: Fabry's Disease Therapeutics Market, Global, Revenue ($m), 2005-2010 15

Figure 8: Fabry's Disease Therapeutics Market, Global, Forecast ($m), 2010-2018 16

Figure 9: Fabry's Disease Therapeutics Market, The US, Revenue ($m), 2005-2010 17

Figure 10: Fabry's Disease Therapeutics Market, The US, Forecast ($m), 2010-2018 18

Figure 11: Fabry's Disease Therapeutics Market, France, Revenue ($m), 2005-2010 19

Figure 12: Fabry's Disease Therapeutics Market, France, Forecast ($m), 2010-2018 20

Figure 13: Fabry's Disease Therapeutics Market, Germany , Revenue ($m), 2005-2010 21

Figure 14: Fabry's Disease Therapeutics Market, Germany, Forecast ($m), 2010-2018 22

Figure 15: Fabry's Disease Therapeutics Market, Italy, Revenue ($m), 2005-2010 23

Figure 16: Fabry's Disease Therapeutics Market, Italy, Forecast ($m), 2010-2018 24

Figure 17: Fabry's Disease Therapeutics Market, Spain, Revenue ($m), 2005-2010 25

Figure 18: Fabry's Disease Therapeutics Market, Spain, Forecast ($m), 2010-2018 26

Figure 19: Fabry's Disease Therapeutics Market, The UK, Revenue ($m), 2005-2010 27

Figure 20: Fabry's Disease Therapeutics Market, The UK, Forecast ($m), 2010-2018 28

Figure 21: Fabry's Disease Therapeutics Market, Japan, Revenue ($m), 2005-2010 29

Figure 22: Fabry's Disease Therapeutics Market, Japan, Forecast ($m), 2010-2018 30

Figure 23: Opportunity and Unmet Need in the Fabry's Disease Therapeutics Market, 2011 33

Figure 24: Strategic Competitor Assessment of the Marketed Products in Fabry's Disease Therapeutics, 2011 34

Figure 25: Fabry's Disease Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2011 41

Figure 26: Fabry's Disease - Clinical Pipeline by Phase of Development (%), 2011 41

Figure 27: Technology Trends Analytics Framework, 2011 42

Figure 28: Technology Trends Analytics Framework - Description, 2011 42

Figure 29: Fabry's Disease, Global, Clinical Trials by Country, 2011 45

Figure 30: Fabry's Disease, Global, Clinical Trials by Phase (%), 2011 46

Figure 31: Fabry's Disease, Global, Clinical Trials by Status of Development (%), 2011 47

Figure 32: Fabry's Disease, Global, Overall Sponsors (%), 2011 48

Figure 33: Fabry's Disease, Global, Prominent Sponsors (%), 2011 49

Figure 34: Fabry's Disease, Global, Top Companies by Phase, 2011 50

Figure 35: Fabry's Disease Market, Drivers and Barriers, 2011 51

Figure 36: Implications for Future Market Competition in the Fabry's Disease Therapeutics Market, 2011 52

Figure 37: Fabry's Disease Market, Clinical Pipeline by Company, 2011 54

Figure 38: GlobalData Market Forecasting Model 65

Companies mentioned

GlaxoSmithKline

Amicus

To order this report:

Therapy Industry: Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker